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Abstract
Background: 3beta,6beta,16beta-trihydroxylup-20(29)-ene is a lupane triterpene isolated from Combretum leprosum
fruit. The lupane group has been extensively used in studies on anticancer effects; however, its possible activity
against protozoa parasites is yet poorly known. The high toxicity of the compounds currently used in leishmaniasis
chemotherapy stimulates the investigation of new molecules and drug targets for antileishmanial therapy.
Methods: The activity of 3beta,6beta,16beta-trihydroxylup-20(29)-ene was evaluated against Leishmania (L.)
amazonensis by determining the cytotoxicity of the compound on murine peritoneal macrophages, as well as its
effects on parasite survival inside host cells. To evaluate the effect of this compound on intracellular amastigotes,
cultures of infected macrophages were treated for 24, 48 and 96 h and the percentage of infected macrophages
and the number of intracellular parasites was scored using light microscopy.
Results: Lupane showed significant activity against the intracellular amastigotes of L. (L.) amazonensis. The
treatment with 109 μM for 96 h reduced in 80 % the survival index of parasites in BALB/c peritoneal macrophages.
At this concentration, the triterpene caused no cytotoxic effects against mouse peritoneal macrophages.
Ultrastructural analyses of L. (L.) amazonensis intracellular amastigotes showed that lupane induced some
morphological changes in parasites, such as cytosolic vacuolization, lipid body formation and mitochondrial
swelling. Bioinformatic analyses through molecular docking suggest that this lupane has high-affinity binding with
DNA topoisomerase.
Conclusion: Taken together, our results have showed that the lupane triterpene from C. leprosum interferes with
L. (L.) amazonensis amastigote replication and survival inside vertebrate host cells and bioinformatics analyses
strongly indicate that this molecule may be a potential inhibitor of topoisomerase IB. Moreover, this study opens
major prospects for the development of novel chemotherapeutic agents with leishmanicidal activity.
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Background
Leishmaniasis is a neglected disease caused by several
protozoan species of the genus Leishmania, an intracellu-
lar parasite that infect cells of the mononuclear phagocyte
system. These protozoan parasites cause a number of im-
portant human diseases, including cutaneous, mucocu-
taneous and visceral leishmaniasis. The parasites are
transmitted by sandflies of the genera Phlebotomus (old
World) and Lutzomyia (New World) by inoculation of
infective metacyclic promastigote forms during the blood
meal. These infective metacyclic forms are internalized by
host macrophages and differentiate into amastigote forms
that are able to proliferate within the phagolysosomes of
mammalian macrophages, thus being responsible for the
maintenance and propagation of the infection [1].
The first-line compounds for the treatment of Leish-
maniasis consists of pentavalent antimonials, sodium
stibogluconate and meglumine antimoniate. The second
line of drugs includes pentamidine and amphotericin B
(also formulated as liposomes). Most of these drugs
present high toxicity, several side effects, and require
long-term management, complicating the conclusion of
treatment. Discovered in the mid-1980s, miltefosine is
orally active antileishmanial drug, approved in India in
2002 for the therapy of leishmaniasis; but its efficacy on
the treatment of American cutaneous leishmaniasis has
been shown to be variable depending on the causative
species, moreover this drug is associated with thera-
peutic complications [2, 3].
Plant extracts have been traditionally used in the treat-
ment of protozoan diseases; in addition, a number of
alternative compounds with antileishmanial activity have
been described, including chalcones, alkaloids, triter-
penes, acetogenins [4–9]. Despite of the activity of sev-
eral compounds in experimental murine leishmaniasis
models, the development of a single drug or formulation
has been hindered by factors such as visceral and cuta-
neous sites of infection, intrinsic variation of the Leish-
mania species known to infect humans, and, finally,
cytotoxicity [10].
Combretum leprosum Mart., a member of the family
Combretaceae, contains many compounds, such as tri-
terpenes, flavonoids, stilbenes, phenantrenes, lignans,
alkaloids [11, 12]. In a phytochemical study of C. lepro-
sum roots and leaves, Facundo et al. [11] have isolated
arjunolic and mollic acids and 3β,6β,16β-trihydroxylup-
20(29)-ene, and found out that the arjunolic acid has
potent anti-inflammatory, anti-nociceptive and anticho-
linesterasic properties [12, 13]. Previous studies from
our laboratory have revealed that 3β,6β,16β-triidrox-
ilup-20(29)-ene obtained from C. leprosum fruit extracts
exhibited anti-leishmanial activity against L. (L.) amazo-
nensis promastigotes, with an IC50 of 3.3 μg/mL [14].
L. (L.) amazonensis is a species transmitted mainly in
the Amazon region and causes diffuse cutaneous leish-
maniasis (DCL) [15]. This species can be associated
with localized and benign cutaneous lesions and can
also cause mucocutaneous leishmaniasis [16]. Diffuse
cutaneous leishmaniasis (DCL) is a form of cutaneous
leishmaniasis that begins as localized and non-ulcerated
papules or nodules that then spread to several parts of the
body [15–17]. Although rare, DCL is a disease that does
not respond to treatments in satisfactory manner [18].
There is an urgent need of new, effective and safe
drugs for a better control of leishmaniasis. Therefore,
new targets need to be set in order to pursue the devel-
opment of a newer generation of anti-protozoan drugs,
and amongst potential molecular targets, DNA topoi-
somerases warrant special attention. DNA topoisome-
rases IB are ubiquitous enzymes responsible for relaxing
superhelical tension in DNA by forming a transient co-
valent nick in one strand of the DNA duplex [19]. DNA
topoisomerase inhibitors represent a main class of anti-
cancer drugs with an increasing number of compounds
which are nowadays in clinical use. These enzymes have
been also proposed as potential targets for the deve-
lopment of anti-protozoan drugs, such as pathogenic
trypanosomatids, including Leishmania spp. [20–22].
In addition, the significant differences in homology be-
tween leishmania DNA topoisomerase IB and the human
form provide a new lead in the study of the structural
determinants that can be targeted [21].
The present study investigated the effects of 3β,6β,16β-
triidroxilup-20(29)-ene on the development of L. (L.)
amazonensis amastigotes within peritoneal mouse mac-
rophages. Furthermore, the potential affinity between
leishmania DNA topoisomerase IB and 3β,6β,16β-trii-
droxilup-20(29)-ene was also studied using bioinformat-
ics molecular docking analyses.
Methods
Plant material
Fruits of Combretum leprosum Mart. were collected in
Viçosa, Ceará State, Brazil, whereas the plant species were
identified by Dr. Afrânio Fernandes (Federal University of
Ceará, Fortaleza). A voucher specimen was deposited in
the Herbarium Prisco Bezerra of the Biology Department,
Federal University of Ceará, Brazil, as number 12446. As
previously described, the 3β,6β,16β-triidroxilup-20(29)-
ene (Fig. 1) was obtained by liquid chromatography over
silica gel [11].
Mice and parasites
Female BALB/c mice aged eight to ten weeks were ob-
tained from the breeding stock of Research Institute for
Tropical Diseases - IPEPATRO, Porto Velho, RO, Brazil.
Promastigotes of Leishmania (Leishmania) amazonensis
PH8 strain (IFLA/BR/67/PH8) were axenically cultured
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at 23 °C in RPMI 1640, supplemented with 10 % heat-
inactivated fetal bovine serum (FBS), 20 mM Hepes (N-
2-hydroxyetrylpiperazine-N’-2-ethanesulfonic acid), and
50 μg/mL of gentamycin. On the 5th day of culture (sta-
tionary phase of growth), promastigotes were harvested
and washed with RPMI by centrifugation at 1000 × g for
15 min. Parasite pellets were then resuspended in cul-
ture medium and used for infection of peritoneal macro-
phages in vitro.
Toxicity on macrophages
With the purpose of evaluating the cytotoxicity of
lupane against host cells, thyoglicholate-elicited periton-
eal macrophages were incubated at different concentra-
tions (6,5 – 218 μM) of triterpene for 24 h, 48 h and
96 h, at 37 °C, under an atmosphere of 5 % CO2. The
samples were dissolved in ethanol. Up to 1 % (v/v), etha-
nol had no effect on macrophage viability and parasite
growth. The viability of macrophages was determined
using a CellTiter 96 Aqueous Non-Radioactive cell pro-
liferation assay (Promega), following the manufacturer’s
instructions. Three independent experiments were per-
formed in duplicate.
Macrophage infection and parasite survival
The effects of C. leprosum lupane on parasite replication
and survival in host macrophages were evaluated by
plating BALB/c thyoglycholate-elicited peritoneal macro-
phages into coverslips placed into 24-well culture plates
and infecting them with L. (L.) amazonensis promasti-
gotes at a ratio of 10:1 for 18 h at 34 °C in an atmos-
phere of 5 % CO2. Free parasites were removed by
washing the macrophages thoroughly before adding the
drugs. The infected cultures were treated with 109 μM
lupane. A control for the solvent used to dissolve lupane
(ethanol) was also included. The cultures were incubated
at 34 °C, 5 % CO2, and analyzed at 24, 48 and 96 h post-
treatment [23]. Infected macrophages incubated without
drugs were used as control, whereas Glucantime® was
used as a control drug at 546,5 μM. In order to estimate
the survival index, the coverslips were stained with May
Grünwald-Giemsa [24] and 100 macrophages were scored
by light microscopy, either as infected or non-infected.
Likewise, these preparations were assessed for the number
of parasites inside the macrophages. The survival index
was determined by multiplying the number of infected
cells by the mean number of amastigotes per cell. The re-
sults were used to establish a proportion in relation to the
control and hence express the result as a percentage.
Transmission electron microscopy
Control and treated infected-macrophages were washed
with Phosphate Buffer Saline (PBS) and fixed with 2.5 %
glutaraldehyde in 0.1 M cacodilate buffer (pH 7.2).
These cells were detached by gently scraping immedi-
ately after the addition of glutaraldehyde and then incu-
bated at room temperature for 1 h. Cells were post-fixed
in a solution containing 1 % OsO4 and 0.8 % potassium
ferricyanide, for 1 h, dehydrated in a graded series of
acetone, and embedded in Epon resin. Ultrathin sections
were stained with uranyl acetate and lead citrate and im-
ages were obtained using a Zeiss 900 transmission elec-
tron microscope.
Homology modeling
The PARMODEL web server [25] has been used to model
the DNA topoisomerase IB (EC 5.99.1.2) from Leishmania
braziliensis in apo form (gene name: LbrM20_V2.3020).
The atypical heterodimeric DNA topoisomerase IB from
Leishmania is composed of a large subunit containing the
phylogenetically conserved “core” domain and a small
subunit harboring the C-terminal region with the tyrosine
residue common in the active site. This study was carried
out on the model of this conserved core that consisted of
430 amino acids. Therefore, we have used the atomic co-
ordinates of topoisomerase IB from Leishmania donovani
(PDB access code: 2b9s) [19], which presents 93.25 %
identity with the DNA topoisomerase IB (EC 5.99.1.2)
from Leishmania braziliensis (LbTOPO). PARMODEL is a
parallelized version of the MODELLER web server [26].
All water molecules and DNA atomic coordinates were re-
moved from the topoisomerase IB structure (PDB access
code: 2b9s) so that the template structure was prepared.
The modeling procedure begins from the alignment of the
sequence to be modeled (target) with a related three-
dimensional structure (template). The alignment being
considered is usually the input to the program while, on
the other hand, the output is a three-dimensional model
for the target sequence containing all main-chain and
Fig. 1 Chemical structure of a natural Lupane [3β,6β,16β-triidroxilup-
20(29)-ene] isolated from Combretum leprosum fruits
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side-chain non-hydrogen atoms. In the modeling
process, a total of 100 models were generated and the
final model was selected based on objective function of
the MODELLER.
Molecular docking
Docking applications can be classified as a function of
their search algorithm, which is defined by a set of rules
and parameters applied to predict the conformations.
When considering the flexibility of the ligand and/or the
receptor, docking algorithms can be classified into two
major groups: rigid-body and flexible docking. We have
applied the flexible docking protocol available in the pro-
gram MolDock [27], wherein the flexibility of the ligand is
simulated. MolDock is an implementation of a heuristic
search algorithm that joins together differential evolution
and a cavity calculation algorithm. In addition, MolDock
evaluates the best poses applying a docking scoring func-
tion, which is used to piecewise linear potential (PLP),
previously implemented in the program GEMDOCK [28].
As for MolDock, the docking scoring function is extended
with an additional term, taking hydrogen bond direction-
ality into account. Furthermore, a re-ranking procedure is
also applied in order to augment docking accuracy.
The present docking simulation was based on a previ-
ously described protocol applied to Leishmania dono-
vani DNA topoisomerase crystal structure (PDB access
code: 2b9s). In this protocol the core domain of topo-
isomerase structure has been used as a target for the
docking simulations. A site known to have important
residues (Arg-314, Lys-352 and Arg-410) can only be ex-
posed by removing the DNA molecule. The structure of
LbTOPO was modeled without DNA or water mole-
cules, as described above.
Lupeol was previously proposed as an important
pharmacophore for topoisomerase I inhibition [29]. As
regards what has been described, we have employed the
lupeol core to access the ZINC database [30] and then
build a small-molecule database. A total of 100 molecules
were retrieved and used to build this database, which is
available for download at http://zinc.docking.org/ [31].
Molecular docking simulations were carried out employ-
ing a validated protocol previously described [32].
Statistical analyses
Results were presented as mean ± S.D. and were statisti-
cally evaluated by Two-Way ANOVA Repeated Mea-
sures, followed by the Tukey test at significance level
of ≤ 0.05.
Ethics Statement
All animals were handled in strict accordance with good
animal practice as defined by the relevant national and/
or local animal welfare bodies, and all animal work was
approved by the Animal Use Ethics Committee of IPE-
PATRO (registration number 2008/4).
Results
Evaluation of macrophage viability
Murine peritoneal macrophages were treated with the
lupane 0.31 - 10 μg/mL (6.5 – 218 μM) to test the po-
tential toxic effect of this substance on mammalian cells.
After 24 – 96 h of incubation, cell viability was checked
by the MTS cell proliferation assay. Lupane showed no
cytotoxic effect at the concentration range of 6.5 –
109 μM. However, at 218 μM, this compound was seen
to be toxic to the macrophages (Fig. 2). Ethanol, used to
dilute the compound, showed no cytotoxicity at the con-
centration used in the test (1 % v/v) (data not shown).
Lupane effects on L. (L.) amazonensis survival in the host
cell
The effects of the triterpene 3β,6β,16β-triidroxilup-20(29)-
ene on the viability of L. (L.) amazonensis intracellular
amastigotes were evaluated during 96 h of incubation
(Fig. 3). The survival index was 100 % for cells of control,
57.9 % for cells treated with lupane 5 μg/mL (109 μM),
and 47.2 % for cells treated with Glucantime® (546,5 μM)
after 24 h of treatment. At 48 h, the survival index was
60.3 and 92.3 % for lupane-treated and glucantime-treated
cells, respectively, whereas the control was determined to
be 100 %. There was an increase of 34 % parasite growth
within glucantime-treated macrophages, whereas the rate
of infection of lupane-treated macrophages remained near
60 %. As for the longest time analyzed (96 h), the survival
index was close to 100 % for the control and glucantime-
treated cells, and 16.2 % for lupane-treated cells, thereby
Fig. 2 Effect of 3β,6β,16β-triidroxilup-20(29)-ene on macrophage
viability. Cytotoxicity of lupane was evaluated in mouse peritoneal
macrophages by the MTS assay test, as described in Materials and
Methods. Percentage of viability was determined using cells cultivated
in medium alone at 100 % viability
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reducing the infection rate by 83 % (Fig. 3a). The survival
index of macrophages treated with the lupane was sig-
nificantly lower (F = 37.4; p < 0.0001) as compared to
the index measured with control macrophages, suggest-
ing that lupane affects the survival of parasites inside
macrophages.
In the lupane-treated macrophages, infection was re-
duced when compared to the control and glucantime-
treated macrophages, which showed parasites multiplying
progressively (Fig. 3b). At 24 h post-treatment, the mean
number of intracellular amastigotes in Glucantime® and
lupane-treated macrophages was lower than that in the
control cells (33 % and 15 % respectively). Nevertheless,
after 96 h, macrophages treated with Glucantime® were
seen to harbor a number of parasites comparable to the
control cells, indicating that this treatment did not inter-
fere with parasite replication. In turn, at this time point,
macrophages treated with lupane have harbored a signifi-
cantly lower number of parasites (F = 8.6; p = 0.0002) as
compared to control (Fig. 3b). These results indicate that
the C. leprosum isolated compound inhibited parasite
growth inside the macrophages.
Transmission electron microscopy was used to investi-
gate the effects of lupane on the peritoneal macrophages
infected with L. (L.) amazonensis. Control-infected cells
have exhibited a normal morphology with macrophages
containing protozoa (Fig. 4a), and dividing parasites
were sometimes observed (Fig. 4b). The ultrastructure of
L. (L.) amazonensis amastigotes internalized in macro-
phages treated with lupane (109 μM) for 48 h was clearly
affected, since parasites presented cytoplasmic extraction
(Fig. 4c P1 asteristic) and membrane profiles in the re-
gion of the flagellar pocket (Fig. 4c, P2 and inset Fig. 4d).
The nucleus of treated parasites contained a less con-
densed chromatin; however the kinetoplast DNA top-
ology was not affected. Lipid vacuoles were noted in the
parasite cytosol and parasite membrane shedding was
observed (Fig. 4e). Mitochondrial swelling was also ob-
served as well as protozoa visibly destroyed inside vacu-
oles (Fig. 4c, P3, Fig. 4f ).
Molecular docking of lupane and DNA topoisomerase
The small-molecule database applied in the present
work was built using the lupeol core as a source of in-
spiration. Former studies have identified DNA topoisom-
erase inhibitory activity in several triterpenes, with
micromolar levels of inhibitory potency [29]. These stud-
ies strongly suggest that such moiety deserves further in-
vestigation as a potential DNA topoisomerase inhibitor.
Analyses of 100 docked structures have indicated a score
ranging from −15 to −41, the lowest score being consid-
ered the highest-affinity ligand. The analyses of molecu-
lar docking simulations (100 docked structures) against
the active site of LbTOPO have revealed that lupane was
the best ligand, whose lowest score was −41.03. Fig. 5a
shows this ligand docked to the active site of LbTOPO.
The analysis of the protein-ligand interaction has re-
vealed the participation of intermolecular hydrophobic
contacts and hydrogen bonds. All hydroxyl groups
present in the lupane participate in intermolecular
hydrogen bonds. The main chain carbonyl oxygen and
amide nitrogen of Arg 190 participate in hydrogen
bonds with a hydroxyl group of lupane. The side chain
of Arg 190 makes a strong intramolecular hydrogen
bond with the side chain of Asp 353 in the LbTOPO
structure, which provides further stability to the struc-
ture, working as an anchor for the hydroxyl group of
lupane. All the side chains of residues Lys 319, Thr 326
Fig. 3 Effect of lupane on the development of Leishmania (L.)
amazonensis within peritoneal macrophage. Infected mouse peritoneal
macrophages were treated with 109 μM of lupane or 546,5 μM of
Glucantime® for up to 96 h. The survival index (a) and the number
of intracellular amastigotes (b) was determined at the indicated
times. Each bar represents the mean ± standard error of at least
three independent experiments, which were performed in duplicate.
Statistically significant differences (p ≤ 0.05) between treated and
non-treated groups are indicated by (*)
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and Lys 352 participate in intermolecular hydrogen
bonds; overall, 5 interactions of this type are observed in
the LbTOPO-lupane complex. Lys 352 has been previ-
ously identified as an important residue of intermolecular
interaction in the structure of topoisomerase IB from L.
(L.) donovani [19]. Likewise, Arg 314 has been proposed
as an important spot for intermolecular interaction. In the
present structure, the side chain of Arg 314 is about 4 Å
Fig. 4 Effect of lupane on the ultrastructure of intracellular amastigotes of L. (L.) amazonensis. (a-b) control cells, in B a dividing protozoa. (c)
Lupane treatment (109 μM) for 48 h promoted cytosolic extraction in P1, followed by complete parasite destruction (P3). (d) Inset of P2 in Fig. c
to observe membrane profiles (arrows) in the flagellar pocket region. (e) Membrane shedding (arrows), lipid vacuoles (LV) and the nucleus
exhibiting a less compact chromatin (arrowhead). (f) A destroyed parasite inside a cytosolic vacuole. Note mitochondrial swelling with enlarged
cristae (M). Arrows indicate subpellicullar microtubules; F – flagellum; FP – flagellar pocket; K – kinetoplast; M – parasite mitochondria; MN – macrophage
nucleus; N – parasite nucleus; P1, P2 and P3 – intracellular amastigotes; VP – vacuole parasitophorous. Bars = 0.5 μm
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away from the lupane, i.e., the limit for Van der Waals
contacts. The analysis of electrostatic molecular surface
indicates the presence of a hydrophilic patch in the bind-
ing pocket, which favors polar interactions with the
hydroxyl groups (Fig. 5b).
Discussion
The antileishmanial activity of the lupane triterpene iso-
lated from fruits of Combretum leprosum was first de-
scribed in a previous study, confirming that this plant
has a potential antiprotozoal action [14]. Both the crude
extract and the isolated lupane have potent toxic activity
against L. (L.) amazonensis promastigotes. The present
work revealed that the 3β,6β,16β-trihydroxylup-20(29)-
ene is also effective in eliminating the L. (L.) amazonen-
sis intracellular amastigotes. At the concentration of
109 μM, no cytotoxicity of lupane has been detected on
mouse peritoneal macrophages during the experimental
period. However, as expected, concentrations above
218 μM showed a significant level of toxicity in the
macrophages.
In a related study, a betulinic aldehyde isolated from
Doliocarpus dentatus (Aubl.) showed in vitro activity
against L. (L.)amazonensis amastigotes, but also showed
toxicity against peritoneal macrophages [33]. There is few
published data concerning the action of lupanes against
protozoa parasites [34, 35], and most studies focused the
antitumoral activity of these substances [36–39].
Sarek et al. [40] and Kommera et al. [36] demon-
strated that minor structural changes on compounds
derived from lupane interfere with the in vitro cytotoxic
activity against tumor cell lines, suggesting a structure-
activity relationship. Our group showed that structural
modifications in natural 3β,6β,16β-trihydroxylup-20(29)-
ene, such as the presence of acetyl groups at 3β and 16β
abolished its leishmanicidal activity. On the other hand,
the replacement of hydroxyl groups by carbonyl groups
did not significantly affect its leishmanicidal activity
[14]. A recent study from our laboratory compared the
lupane leishmanicidal activity against different Leihs-
mania species and demonstrated that this triterpene
also had a potent anti-proliferative effect against the
promastigotes of L. braziliensis and L. guyanensis (un-
published results).
The 3β,6β,16β-trihydroxylup-20(29)-ene concentration
adopted in this study was sufficient to reduce the rate of
infected macrophages and the number of intracellular
amastigotes from 24 h-post treatment onwards. The ef-
fect of lupane was time-dependent, reaching a survival
index of 16 at 96 h-post treatment. Furthermore, lupane
showed a higher inhibitory activity on the growth of
leishmania parasites as compared to that of Glucantime®.
Maes et al. [6] have analyzed the action of six triter-
penes saponins isolated from a Vietnamese plant Maesa
balansae Mez. (Myrsinaceae) against L. donovani and L.
infantum. The triterpene saponins from M. balansae in-
hibit the intracellular growth of L. infantum amastigotes
and the subcutaneous administration of 0.4 mg/kg of
the substance in BALB/c mice infected with L. donovani
was able to reduce the parasite load by 95 %. Addition-
ally, the triterpene saponin named Maesabalide III had
the most potent antileishmanicidal activity in vivo
towards L. donovani-infected hamsters, leading to a
99.8 % reduction of the parasite load after a seven-day
treatment [41].
Glucantime®, which is one of the drugs currently used
in the treatment of leishmaniasis, was unable to reduce
infection over the time analysed. Infected cells treated
with Glucantime® showed a survival index of 47.2 at
24 h, but this index was seen to increase to 98.8 at 96 h.
Since the 40s’, pentavalent antimonials are the drugs of
choice for the treatment of leishmaniasis; however, the
mechanism of action of two of them - meglumine anti-
moniate (Glucantime®) and sodium stibogluconate - is
not well known. Several studies suggest that pentavalent
antimony may be a pro-drug and that it can be con-
verted into trivalent antimony inside the infected cell
possibly interfering in the process of glycolysis of the
parasite. Moreover, it could affect enzyme inhibition and
thereby lead to the depletion of intracellular ATP levels
[42, 43]. Unfortunately, these drugs cause severe side
effects and the treatment is usually extensive.
In this work, the parasite ultrastructure was affected
by the treatment with lupane, since cells exhibited loss
Fig. 5 Docking of lupane at the topoisomerase IB (LbTOPO) active site
(a) and eletrostatic molecular surface of active site of topoisomerase IB
where lupane is docked (b)
Teles et al. BMC Complementary and Alternative Medicine  (2015) 15:165 Page 7 of 10
of cytosolic content, which culminated in cell lysis. The
nucleus of the treated leishmania presented a less com-
pact chromatin and it was observed mitochondrial
swelling as previously reported after the use of topo-
isomerase I inhibitors in Trypanosoma cruzi [44].
Zuma et al. [44] showed that Camptothecin and rebec-
camycin, eukaryotic topoisomerase I inhibitors, were
effective in arrest of T. cruzi replication and the ultra-
structural alterations, such as the unpacking of nuclear
heterochromatin and mitochondrial swelling were
observed.
Chowdhury et al. [45] showed that dihydrobetulinic
acid - a derivative of betulinic acid - has antileishmanial
activity against both L. donovani promastigotes and
amastigotes forms, and that it inhibits DNA topoisome-
rases I and II. This pentacyclic triterpenoid causes damage
in nuclear DNA and induces apoptosis in L. donovani
parasites. The same authors have recently demonstrated
that three synthetic derivatives of betulin (disuccinylbetu-
lin, diglutaryldihydrobetulin, and disuccinyldihydro-
betulin) reduced replication of the intracellular L.
donovani amastigotes, in addition to inhibiting the re-
laxation activity of the enzyme type IB topoisomerase
[Leishmania donovani topoisomerase I (LdTOP1LS)] of
the parasite [46].
The analysis of the intermolecular interaction between
3β,6β,16β-trihydroxylup-20(29)-ene and LbTOPO indi-
cates a perfect coupling and a strong binding affinity.
The strong antileshmanial activity interfering with amas-
tigote survival, and the high virtual affinity binding with
LbTPOPO suggest that the 3β,6β,16β-trihydroxylup-
20(29)-ene may be a potential inhibitor of L. (L.) amazo-
nensis topoisomerase IB. The in silico data is necessary
to confirm this inhibiton, but results indicate that the
used bioinformatic analyses were able to identify poten-
tial new antileishmanial drugs.
Type IB topoisomerases are enzymes essential to cell life
which form a covalent bond with the 3’ end of broken
DNA strands. Leishmania type I DNA topoisomerase
differ from their homologues in other eukaryotic cells.
The DNA topoisomerases I from mammalian hosts are
monomeric enzymes, whereas the trypanosomatid type I
DNA topoisomerases are heterodimeric [47, 48]. More-
over, this enzyme has a dual localization in trypanosoma-
tids: in the nucleus, associated with genomic DNA, and
in the kinetoplast, associated with kDNA [49, 50]. These
differences make such enzyme a potential target for
chemotherapeutic intervention in diseases caused by
trypanosomatids parasites.
A big step was taken forward in the development of
drugs over the last years, allowing for the treatment of a
broad spectrum of pathologies. Unfortunately, diseases
caused by protozoan parasites, such as trypanosomes,
leishmania and plasmodia are not included in research
and development programs from the pharmaceutical
sector [51, 52], resulting in a challenging scenario for
the development of new drugs in face of these orphan
diseases.
Conclusion
Finally, the results of this study have revealed that a
natural triterpene, a lupane isolated from C. leprosum,
has antileishmanial activity against L. (L.) amazonensis
intracellular amastigotes and, by bioinformatic analysis,
interacts with type IB parasite DNA topoisomerase.
This compound represents a new source of molecules
for the development of novel antiprotozoal agent and
may be a potential candidate for the treatment of
leishmaniasis.
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